Q-omics provides the consensus-scored ZFYVE26 profile across patient tissues and cancer cell-line models. ZFYVE26 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZFYVE26 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ZFYVE26 protein abundance shows 36,893 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, HNSC, and LSCC as cancer lineages where ZFYVE26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFYVE26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFYVE26 survival associations across molecular data types. ZFYVE26 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFYVE26 RNA expression–survival associations across cancer types. High ZFYVE26 expression shows unfavorable associations in ACC, but favorable associations in BRCA, KIRC, HNSC, SCLC and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for ZFYVE26 RNA expression.
This table summarizes ZFYVE26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZFYVE26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFYVE26 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRP, CHOL and STAD. The HNSC box plot shows higher ZFYVE26 RNA expression in tumor versus normal tissue (log2 FC = +1.187, t-test p < 0.001).
This table shows molecular features associated with ZFYVE26 in patient tissues and cancer cell lines. In patient samples, ZFYVE26 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFYVE26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
